Cogent Biosciences, Inc.
NASDAQ:COGT
10.21 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets: | |||||||||
| Current Assets: | |||||||||
| Cash & Cash Equivalents
| 53.229 | 139.886 | 219.684 | 242.19 | 37.424 | 55.671 | 28.27 | 41.321 | 90.48 |
| Short Term Investments
| 212.481 | 119.39 | 0 | 0 | 0 | 22.923 | 12.691 | 27.187 | 0 |
| Cash and Short Term Investments
| 265.71 | 259.276 | 219.684 | 242.19 | 37.424 | 78.594 | 40.961 | 68.508 | 90.48 |
| Net Receivables
| 0 | 0 | 0 | 0 | 2 | 1.668 | 0.83 | 0.928 | 0.294 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0.075 | 0 | 0 |
| Other Current Assets
| 5.061 | 5.69 | 2.949 | 2.722 | 1.167 | 0.74 | 0.513 | 0.296 | 0.326 |
| Total Current Assets
| 270.771 | 264.966 | 222.633 | 244.912 | 40.591 | 81.002 | 42.379 | 69.732 | 91.1 |
| Non-Current Assets: | |||||||||
| Property, Plant & Equipment, Net
| 30.342 | 31.099 | 4.477 | 4.749 | 7.15 | 3.251 | 4.108 | 4.563 | 2.416 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 7.46 | 0 | 1.255 | 1.255 | 1.255 | 1.255 | 1.255 | 1.255 | 1.255 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 4.864 | 4.745 | 3.727 | 0 | 0.427 | 0.419 | 1.373 | 0 | 0 |
| Total Non-Current Assets
| 42.666 | 35.844 | 9.459 | 6.004 | 8.832 | 4.925 | 6.736 | 5.818 | 3.671 |
| Total Assets
| 313.437 | 300.81 | 232.092 | 250.916 | 49.423 | 85.927 | 49.115 | 75.55 | 94.771 |
| Liabilities & Equity: | |||||||||
| Current Liabilities: | |||||||||
| Account Payables
| 10.655 | 5.842 | 3.483 | 0.732 | 3.183 | 1.519 | 1.346 | 1.454 | 1.395 |
| Short Term Debt
| 1.386 | 1.423 | 2.324 | 2.052 | 1.619 | 3.798 | 2.773 | 1.202 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 25.686 | 1.7 | 7.975 | 3.795 | 1.315 | 17.949 | 6.891 | 5.963 | 5.29 |
| Other Current Liabilities
| 0.441 | 17.884 | 3.295 | 6.515 | 7.131 | 1.679 | 0.18 | 0.118 | 0.606 |
| Total Current Liabilities
| 38.168 | 26.849 | 17.077 | 13.094 | 13.248 | 24.945 | 11.19 | 8.737 | 7.291 |
| Non-Current Liabilities: | |||||||||
| Long Term Debt
| 17.467 | 18.226 | 0.831 | 3.155 | 4.413 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 8.714 | 13.517 | 17.295 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | -0 | 0 | 0.748 | 0.906 | 0.908 | 0.665 |
| Total Non-Current Liabilities
| 17.467 | 18.226 | 0.831 | 3.155 | 4.413 | 0.748 | 9.62 | 14.425 | 17.96 |
| Total Liabilities
| 55.635 | 45.075 | 17.908 | 16.249 | 17.661 | 25.693 | 20.81 | 23.162 | 25.251 |
| Equity: | |||||||||
| Preferred Stock
| 60.035 | 65.83 | 85.4 | 110.881 | 0 | 85.927 | 77.151 | 77.086 | 77.022 |
| Common Stock
| 0.086 | 0.07 | 0.044 | 0.032 | 0.03 | 0.03 | 0.01 | 0.01 | 0.016 |
| Retained Earnings
| -603.624 | -411.214 | -270.973 | -198.7 | -123.892 | -92.059 | -51.339 | -25.847 | -7.723 |
| Accumulated Other Comprehensive Income/Loss
| 0.246 | -0.104 | -0 | 0 | 0 | -0.012 | -0.016 | -0.024 | -0.016 |
| Other Total Stockholders Equity
| 801.059 | 601.153 | 399.713 | 322.454 | 155.624 | 66.348 | 2.499 | 1.163 | 0.221 |
| Total Shareholders Equity
| 257.802 | 255.735 | 214.184 | 234.667 | 31.762 | 60.234 | 28.305 | 52.388 | 69.52 |
| Total Equity
| 257.802 | 255.735 | 214.184 | 234.667 | 31.762 | 60.234 | 28.305 | 52.388 | 69.52 |
| Total Liabilities & Shareholders Equity
| 313.437 | 300.81 | 232.092 | 250.916 | 49.423 | 85.927 | 49.115 | 75.55 | 94.771 |